Michael Hudecek

Myeloma CARs are rolling into the clinical arena.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.

Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 normal lymphocytes.

CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib.

Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.

CARs and other T cell therapies for MM: The clinical experience.

Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system.

CAR T cells targeting αβ integrin are effective against advanced cancer in preclinical models.

Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.

ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

A highly soluble Sleeping Beauty transposase improves control of gene insertion.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Antibody-Based CAR T Cells Produced by Lentiviral Transduction.

β-.

Chemically Programmable and Switchable CAR-T Therapy.

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Inefficient CAR-proximal signaling blunts antigen sensitivity.

New targets and technologies for CAR-T cells.

What is the future of immunotherapy in multiple myeloma?

Overcoming key challenges in cancer immunotherapy with engineered T cells.

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies.

BATF3 programs CD8 T cell memory.

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy.

Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.

Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive immunotherapy for cancer.

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.

T-Cell Metabolism in Graft Host Disease.

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

The era of in vivo T cell engineering.

Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital.

Highjacking myeloma's niche with beefed-up CAR-Ts.

ROR1-targeting switchable CAR-T cells for cancer therapy.

Automated, scaled, transposon-based production of CAR T cells.

CAR T cells targeting are effective at treating invasive pulmonary aspergillosis in preclinical models.

Engineering CD20 CARs with a Twist.

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

Genome Editing in Engineered T Cells for Cancer Immunotherapy.

Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy.

BCMA CAR-T cells in multiple myeloma-ready for take-off?

CAR T-cell therapy in multiple myeloma: mission accomplished?

Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.

Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.

Trust in and Acceptance of Artificial Intelligence Applications in Medicine: Mixed Methods Study.

Mutation-specific CAR T cells as precision therapy for IGLV3-21 expressing high-risk chronic lymphocytic leukemia.

Correction: ROR1-targeting switchable CAR-T cells for cancer therapy.

Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.